Avacta (Group)

https://www.avacta.com

Avacta’s principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development. Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal’s immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets. Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics. *

	Start	2007-11-14 existent
	Industry	analytical instrument
	Industry 2	diagnostics (medical/biological)
	Person	Coughlin, Christina (Avacta 202405– CEO before CytoImmune Therapeutics + Immunocore + Tmunity + Rubius + BIG PHARMA)
	Person 2	Forster, Eliot (F-Star 201810– CEO before Immunocore + Creabilis + Solace Pharmaceuticals + Pfizer + GSK)

	Region	Leeds, West Yorkshire
	Country	United Kingdom (GB)
	Street	Ash Way, Unit 20 Thorp Arch Estate
	City	LS23 7FA Wetherby
	Tel	+44-1904-21-7070
		Address record changed: 2024-05-09

Basic data	Employees	n. a.

		* Document for »About Section«: Selexis S.A.. (6/20/19). "Press Release: Avacta and Selexis Partner to Develop Cell Line for Clinical Manufacturing". Cambridge & Geneva.

		Record changed: 2024-05-09